1.0Sterling Investment Managementhttps://sterlingim.co.ukadmin_ghttps://sterlingim.co.uk/author/admin_g/rich600338<blockquote class="wp-embedded-content" data-secret="iX5NrbyIiK"><a href="https://sterlingim.co.uk/content/company-updates/coca-cola-hbc-ag/">Coca-Cola HBC AG</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://sterlingim.co.uk/content/company-updates/coca-cola-hbc-ag/embed/#?secret=iX5NrbyIiK" width="600" height="338" title="“Coca-Cola HBC AG” — Sterling Investment Management" data-secret="iX5NrbyIiK" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript"> /*! This file is auto-generated */ !function(c,l){"use strict";var e=!1,o=!1;if(l.querySelector)if(c.addEventListener)e=!0;if(c.wp=c.wp||{},c.wp.receiveEmbedMessage);else if(c.wp.receiveEmbedMessage=function(e){var t=e.data;if(!t);else if(!(t.secret||t.message||t.value));else if(/[^a-zA-Z0-9]/.test(t.secret));else{for(var r,s,a,i=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),n=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),o=0;o<n.length;o++)n[o].style.display="none";for(o=0;o<i.length;o++)if(r=i[o],e.source!==r.contentWindow);else{if(r.removeAttribute("style"),"height"===t.message){if(1e3<(s=parseInt(t.value,10)))s=1e3;else if(~~s<200)s=200;r.height=s}if("link"===t.message)if(s=l.createElement("a"),a=l.createElement("a"),s.href=r.getAttribute("src"),a.href=t.value,a.host===s.host)if(l.activeElement===r)c.top.location.href=t.value}}},e)c.addEventListener("message",c.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",t,!1),c.addEventListener("load",t,!1);function t(){if(o);else{o=!0;for(var e,t,r,s=-1!==navigator.appVersion.indexOf("MSIE 10"),a=!!navigator.userAgent.match(/Trident.*rv:11\./),i=l.querySelectorAll("iframe.wp-embedded-content"),n=0;n<i.length;n++){if(!(r=(t=i[n]).getAttribute("data-secret")))r=Math.random().toString(36).substr(2,10),t.src+="#?secret="+r,t.setAttribute("data-secret",r);if(s||a)(e=t.cloneNode(!0)).removeAttribute("security"),t.parentNode.replaceChild(e,t);t.contentWindow.postMessage({message:"ready",secret:r},"*")}}}}(window,document); </script> Shield Therapeutics will receive a £1m milestone payment from KYE Pharma following the signing of an agreement for the development and commercialization of its Accrufer iron deficiency treatment in Canada, opening up another new market. Given the significant benefits of this treatment over conventional alternatives, we have no doubt that Shield will continue to expand its reach into additional territories going forward. These small milestone payments are a sideshow – all eyes are on their US performance, a market where the company is building momentum through direct sales.https://sterlingim.co.uk/wp-content/uploads/2022/05/social.png200200